The handheld machines are also being deployed to detect mutant strains of Covid-19.
It has announced it will go public in London in the second half of this year, with founder Dr Gordon Sanghera saying that while 2020 was a ‘pivotal year’, the firm is: “still only in the foothills of what is possible.”
The float will also bring a potential payday for investors in Neil Woodford’s collapsed Patient Capital fund now being managed by Schroders: Nanopore is the second largest holding in the Schroder UK Public Private trust at 13.7% of the portfolio.
But the benefits will be missed by those in the far bigger Woodford Equity Income Fund, whose stake was sold last year by administrator Link to Acacia Research, a US-based fund being advised by Woodford.
Acacia bought the 6% stake in Nanopore from for £97.8 million in June. Current estimates suggest it is now worth roughly double that sum.
